UBS Group’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-13
| Closed | -$96 | – | 10773 |
|
|
2026
Q1 | $96 | Sell |
13
-27
| -68% | -$176 | ﹤0.01% | 10125 |
|
|
2025
Q4 | $252 | Sell |
40
-316
| -89% | -$1.84K | ﹤0.01% | 10077 |
|
|
2025
Q3 | $1.39K | Buy |
356
+315
| +768% | +$1.29K | ﹤0.01% | 9360 |
|
|
2025
Q2 | $188 | Sell |
41
-1,999
| -98% | -$8.57K | ﹤0.01% | 9936 |
|
|
2025
Q1 | $9.96K | Sell |
2,040
-12,800
| -86% | -$77.7K | ﹤0.01% | 8662 |
|
|
2024
Q4 | $99.7K | Buy |
14,840
+14,800
| +37,000% | +$110K | ﹤0.01% | 6878 |
|
|
2024
Q3 | $308 | Sell |
40
-702
| -95% | -$4.23K | ﹤0.01% | 9006 |
|
|
2024
Q2 | $4.45K | Sell |
742
-6,409
| -90% | -$48.7K | ﹤0.01% | 8091 |
|
|
2024
Q1 | $64.5K | Buy |
7,151
+2,234
| +45% | +$20.4K | ﹤0.01% | 6399 |
|
|
2023
Q4 | $46.6K | Buy |
4,917
+1,502
| +44% | +$13.2K | ﹤0.01% | 6575 |
|
|
2023
Q3 | $40.6K | Sell |
3,415
-316
| -8% | -$5.6K | ﹤0.01% | 6432 |
|
|
2023
Q2 | $91.4K | Sell |
3,731
-5,999
| -62% | -$156K | ﹤0.01% | 6083 |
|
|
2023
Q1 | $305K | Sell |
9,730
-12,884
| -57% | -$746K | ﹤0.01% | 5074 |
|
|
2022
Q4 | $1.59M | Buy |
22,614
+20,151
| +818% | +$1.49M | ﹤0.01% | 3612 |
|
|
2022
Q3 | $212K | Buy |
2,463
+2,213
| +885% | +$215K | ﹤0.01% | 5034 |
|
|
2022
Q2 | $21K | Sell |
250
-16,041
| -98% | -$1.41M | ﹤0.01% | 6814 |
|
|
2022
Q1 | $2.71M | Buy |
16,291
+6,479
| +66% | +$930K | ﹤0.01% | 3138 |
|
|
2021
Q4 | $1.64M | Buy |
9,812
+7,873
| +406% | +$889K | ﹤0.01% | 3922 |
|
|
2021
Q3 | $167K | Sell |
1,939
-4,721
| -71% | -$312K | ﹤0.01% | 5453 |
|
|
2021
Q2 | $361K | Buy |
6,660
+6,159
| +1,229% | +$350K | ﹤0.01% | 4957 |
|
|
2021
Q1 | $30K | Sell |
501
-97
| -16% | -$5.67K | ﹤0.01% | 7015 |
|
|
2020
Q4 | $31K | Buy |
598
+229
| +62% | +$12.7K | ﹤0.01% | 6599 |
|
|
2020
Q3 | $18K | Sell |
369
-415
| -53% | -$19.8K | ﹤0.01% | 6393 |
|
|
2020
Q2 | $41K | Sell |
784
-1,021
| -57% | -$51.5K | ﹤0.01% | 6032 |
|
|
2020
Q1 | $79K | Sell |
1,805
-120
| -6% | -$4.88K | ﹤0.01% | 5477 |
|
|
2019
Q4 | $77K | Buy |
1,925
+172
| +10% | +$5.29K | ﹤0.01% | 6126 |
|
|
2019
Q3 | $58K | Buy |
1,753
+1,430
| +443% | +$69K | ﹤0.01% | 6114 |
|
|
2019
Q2 | $25K | Buy |
+323
| New | +$50.2K | ﹤0.01% | 6463 |
|
|
2019
Q1 | – | Sell |
-190
| Closed | -$45K | – | 7951 |
|
|
2018
Q4 | $45K | Buy |
190
+5
| +3% | +$1.22K | ﹤0.01% | 6186 |
|
|
2018
Q3 | $40K | Buy |
+185
| New | +$32.3K | ﹤0.01% | 6330 |
|
UBS Group's KZR Position: Q2 2026 in Review
UBS Group sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 13 shares — an estimated $96 sold.
UBS Group first reported a position in KZR in Q3 2018 and held it in 30 quarters. The position peaked at $2.71M in Q1 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- UBS Group reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 13 Kezar Life Sciences shares in Q2 2026, an estimated $96.
- UBS Group first reported a position in Kezar Life Sciences in Q3 2018 and held it in 30 quarters.
- UBS Group's Kezar Life Sciences position peaked at $2.71M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.